Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With Rituximab (MabThera) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment

Trial Profile

An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With Rituximab (MabThera) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Sargramostim (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 04 Jul 2012 Companies added in the association field as reported by EudraCT.
  • 04 Jul 2012 Actual initiation date 19 Sep 2008 added as reported by EudraCT.
  • 04 Jul 2012 Status changed from not yet recruiting to recruiting as reported by EudraCT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top